Chief Scientist Professor Wang Jianxun Visits the National Clinical Research Center for Kidney Diseases, Discusses New Applications of Cell Therapy with Academician Liu Zhihong

On June 17, Chief Scientist Professor Wang Jianxun visited the National Clinical Research Center for Kidney Diseases at the Eastern Theater Command General Hospital for exchange and discussion, engaging in in-depth conversations with Academician Liu Zhihong's team on the clinical research and application of cell therapy in kidney diseases. Dr. Fu Yuchen, Senior R&D Scientist of our company, accompanied the visit.

Academician Liu Zhihong is a member of the Chinese Academy of Engineering, a member of the Academic Division of the Chinese Academy of Medical Sciences, a Standing Director of the Council of the Chinese Medical Association, the ninth Chairperson of the Chinese Society of Nephrology, and a Standing Director of the International Society of Nephrology (ISN). She serves as the Director of the National Clinical Research Center for Kidney Diseases at the Eastern Theater Command General Hospital and has led numerous national key research projects, including the National "973" Program, the National "Precision Medicine" Key R&D Program, major international cooperation projects of the National Natural Science Foundation of China, and major projects of the National Natural Science Foundation of China, with extensive research and clinical practice experience.

Led by Professor Zhang Haitao, Deputy Director of the National Center, and Professor Huang Xianghua, Director of the Cell Therapy Center at the Research Institute, Professor Wang Jianxun and his delegation toured the National Center building, including the biospecimen bank, outpatient clinic, clinical trial center, clinical laboratory, cell therapy center, intensive care unit, and key laboratory.

During the symposium, the two sides engaged in thorough and detailed discussions on clinical research and practical applications of cell therapy in the nephrology field. Professor Wang Jianxun noted that China's cellular immunotherapy sector has developed rapidly in recent years. Shenzhen Cell Valley has established close collaborations with numerous well-known domestic and international hospitals, providing gene-modified and non-gene-modified immune cell preparation services for clinical treatment. The company has earned high industry recognition for its advanced R&D capabilities, robust manufacturing quality, and significant therapeutic outcomes, ensuring that independently developed research results truly serve clinical needs and are widely applied in clinical practice.

Academician Liu Zhihong pointed out that the National Kidney Disease Center has accumulated extensive experience in immunotherapy and cell therapy, with its technology translation work closely tied to clinical platforms, demonstrating outstanding practical capabilities. She highly commended Shenzhen Cell Valley's product technology, noting its potential to play a significant role in the treatment of kidney diseases. She expressed hope that both parties would, while ensuring treatment efficacy and safety, focus on multiple disease types and jointly accelerate the clinical research and application progress of cell therapy in nephrology.

This exchange visit promoted further collaboration between Shenzhen Cell Valley and the National Clinical Research Center for Kidney Diseases. The two parties will jointly explore new pathways for cell therapy in the nephrology field, bringing safer and more effective treatment options to kidney disease patients.

About the National Clinical Research Center for Kidney Diseases at the Eastern Theater Command General Hospital

The Nephrology Department of the Eastern Theater Command General Hospital is one of the earliest established nephrology disciplines in China. It became the first kidney disease center in the People's Liberation Army in 1986. Today, it serves not only as the PLA Kidney Disease Research Institute and a PLA key clinical specialty but also as the Jiangsu Provincial Translational Medicine Center for Kidney Diseases, the Jiangsu Provincial Clinical Research Center for Kidney Diseases, the Jiangsu Medical Innovation Center, and a National Key Clinical Specialty. In 2013, it was approved as one of the first batch of National Clinical Research Centers for Kidney Diseases in China.

After more than 40 years of dedicated development under the leadership of Academician Liu Zhihong, the center has risen to become a world-renowned, domestically leading, modern, and distinctive nephrology specialty. It has earned extensive academic recognition for its high-quality clinical services, superb medical expertise, fruitful innovative achievements, and rigorous work ethic. The discipline has consistently ranked among the top in Fudan University's "China's Best Hospital Specialty Reputation Rankings" for many consecutive years and has repeatedly ranked first in the "National Hospital Internet Influence Ranking" for nephrology, serving millions of patients with kidney diseases.